EcoDrugPlus

Tubulin Alpha 4a

Ensembl ID : ENSSMAG00000037271
Gene Symbol: TUBA4A
1 Cross references
156 Possible Orthologues:

Tubulin Beta-2a Chain-Like

Ensembl ID : ENSSMAG00000020319
Gene Symbol: LOC118311598
3 Cross references
305 Possible Orthologues:

Tubulin, Beta 5

Ensembl ID : ENSSMAG00000026530
Gene Symbol: TUBB5
1 Cross references
209 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSSMAG00000009219
Gene Symbol: TP53
2 Cross references
232 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSSMAG00000011264
Gene Symbol: LOC118319501
2 Cross references
185 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSSMAG00000019336
Gene Symbol: TYR
3 Cross references
202 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSSMAG00000017563
Gene Symbol: TYR
3 Cross references
198 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSSMAG00000009330
Gene Symbol: TH
1 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSSMAG00000004461
Gene Symbol: TYK2
1 Cross references
195 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin-Like And Egf-Like Domains 1

Ensembl ID : ENSSMAG00000020579
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Receptor Ufo

Ensembl ID : ENSSMAG00000020356
Gene Symbol: LOC118299712
2 Cross references
187 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSSMAG00000007370
Gene Symbol: KRAS
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).